{"id":386780,"date":"2016-12-26T00:00:00","date_gmt":"2016-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360te0046-medtech-transcatheter-embolization-and-occlusion-devices-china-2017-market-analysis\/"},"modified":"2026-04-24T11:10:43","modified_gmt":"2026-04-24T11:10:43","slug":"m360te0046-medtech-transcatheter-embolization-and-occlusion-devices-china-2017-market-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/m360te0046-medtech-transcatheter-embolization-and-occlusion-devices-china-2017-market-analysis\/","title":{"rendered":"Transcatheter Embolization and Occlusion Devices | China | 2017 | Market Analysis"},"content":{"rendered":"<p>The Chinese\u00a0market for\u00a0<abbr title=\"Transcatheter Embolization and Occlusion\">TEO<\/abbr>\u00a0devices is a growing, dynamic, and complex market driven by continual device improvement and adoption of new, innovative products from both global and domestic Chinese companies.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for\u00a0<abbr title=\"Transcatheter Embolization and Occlusion\">TEO<\/abbr>\u00a0devices in China\u00a0across a 10-year period.<\/p>\n<p>\u00a0<\/p>\n<p><strong><abbr title=\"Interventional Neuroradiology\">INR<\/abbr>\u00a0flow-diverting devices will become available in China for the first time in 2017 and will be rapidly adopted.<\/strong><\/p>\n<p>How will these devices impact procedure volumes for other\u00a0<abbr title=\"Interventional Neuroradiology\">INR<\/abbr>\u00a0<abbr title=\"Transcatheter Embolization and Occlusion\">TEO<\/abbr>\u00a0devices?<\/p>\n<p>Which competitor will be first to market, and what strategy will each of the competitors adopt in this space?<\/p>\n<p><strong>The embolization particle segment remains one of the most attractive markets in China due to its strong revenue potential.<\/strong><\/p>\n<p>Which types of embolization particles have been adopted most rapidly in China?<\/p>\n<p>How will the high incidence of\u00a0<abbr title=\"Hepatocellular Carcinoma\">HCC<\/abbr>\u00a0in China affect the embolization particle market over the forecast period?<\/p>\n<p>When will radioembolization spheres become available, and what impact will they have on other types of embolization particles?<\/p>\n<p><strong>Mergers and acquisitions have been a defining characteristic of the\u00a0<abbr title=\"Transcatheter Embolization and Occlusion\">TEO<\/abbr>\u00a0device competitive landscape in recent years.<\/strong><\/p>\n<p>How have manufacturers gained a competitive advantage through technology acquisition?<\/p>\n<p>Which market segments are the most dynamic in terms of mergers and acquisitions?<\/p>\n<p>What M&#038;A strategies should foreign and domestic companies adopt, respectively?<\/p>\n","protected":false},"template":"","class_list":["post-386780","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-transcatheter-embolization-and-occlusion-devices","medtech-geography-china","medtech-date-857"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386780\/revisions"}],"predecessor-version":[{"id":575141,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/386780\/revisions\/575141"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=386780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}